within Pharmacolibrary.Drugs.ATC.S;

model S02AA15
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 23 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,
    adminCount     = 1,
    Vd             = 0.15,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Ciprofloxacin is a broad-spectrum fluoroquinolone antibiotic used for the treatment of various bacterial infections, including urinary tract infections, respiratory tract infections, and certain types of gastroenteritis. It is approved for clinical use in many countries and remains a common therapy for susceptible infections.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic parameters in healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Junkert, AM, et al., &amp; Pontarolo, R (2024). Pharmacokinetics of oral ciprofloxacin in adult patients: A scoping review. <i>British journal of clinical pharmacology</i> 90(2) 528–547. DOI:<a href=&quot;https://doi.org/10.1111/bcp.15933&quot;>10.1111/bcp.15933</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37850318/&quot;>https://pubmed.ncbi.nlm.nih.gov/37850318</a></p></li><li><p>Tolentino-Hernández, SJ, et al., &amp; Castañeda-Hernández, G (2020). Oral Ciprofloxacin Pharmacokinetics in Healthy Mexican Volunteers and Other Populations: Is There Interethnic Variability?. <i>Archives of medical research</i> 51(3) 268–277. DOI:<a href=&quot;https://doi.org/10.1016/j.arcmed.2020.02.008&quot;>10.1016/j.arcmed.2020.02.008</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32143939/&quot;>https://pubmed.ncbi.nlm.nih.gov/32143939</a></p></li><li><p>van Rhee, KP, et al., &amp; Knibbe, CAJ (2022). Ciprofloxacin Pharmacokinetics After Oral and Intravenous Administration in (Morbidly) Obese and Non-obese Individuals: A Prospective Clinical Study. <i>Clinical pharmacokinetics</i> 61(8) 1167–1175. DOI:<a href=&quot;https://doi.org/10.1007/s40262-022-01130-5&quot;>10.1007/s40262-022-01130-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35641862/&quot;>https://pubmed.ncbi.nlm.nih.gov/35641862</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end S02AA15;
